IGES Experten vor Ort
18.03.25
Dr. Tilo Mandry | IGES Institut
Moderation
Pannel Discussion: A work of art: Success as a first-time launcher in Europe
Increasingly, smaller biotech companies are launching their new drugs themselves, rather than relying on large pharmaceutical companies to make this happen for them. How can they get it right the first time?
Managers of biotech companies with a drug in late-stage clinical development face a challenge: as their asset progresses well in clinical trials, they need to decide whether to license it out or market it themselves. In the European Union, the number of companies that market only a single pharmaceutical product has increased from four in 2014 to 33 in 2024. This panel will discuss the deciding factors for successfully marketing a product independently in Europe.
Further Panelists:
-Delphine Bourdon | Blueprint Medicines
-Thomas Ballotti | European Medicines Agency
-Daniel Ghyssels | Immunocore
Veranstaltung: BIO-EUROPE SPRING
Kongress
Raum: Exhibit Hall Stage
Veranstaltungssprache: Englisch
Zeit: 10.00 - 10.45 Uhr
